Fractyl Health (GUTS) Preferred Stock Liabilities (2023)
Fractyl Health (GUTS) reported Preferred Stock Liabilities of $287.3 million for Q4 2023, little changed quarter-over-quarter from $287.3 million in Q3 2023.
Fractyl Health (GUTS) has 1 years of Preferred Stock Liabilities data on file, last reported at $287.3 million in Q4 2023.
- For the quarter ending Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $287.3 million; the trailing twelve-month figure through Dec 2023 stood at $287.3 million (changed N/A YoY), and the FY2023 full-year result was $287.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2023 stood at $287.3 million, roughly flat from $287.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $287.3 million in Q1 2023 and bottomed at $287.3 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Fractyl Health | 19.24 Mn | 19.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 287.33 Mn |
| Sep 30, 2023 | 287.33 Mn |
| Jun 30, 2023 | 287.33 Mn |
| Mar 31, 2023 | 287.33 Mn |